Skip to main content
SpringerLink
Log in

Pharmacist-Led Interventions for the Management of Cardiovascular Disease

Opportunities and Obstacles

  • Leading Article
  • Published:
Disease Management & Health Outcomes

Abstract

Given the documented treatment gap for patients with cardiovascular disease, there are numerous opportunities for pharmacists to become more extensively involved in the delivery of care to these high-risk patients.

In published trials, pharmacists have demonstrated improved surrogate outcomes for patients with cardiovascular disease by managing hyperlipidemia, hypertension, and secondary prevention medications. A concentrated effort by pharmacists in the inpatient setting, using a combination of direct provider and patient interventions, has been shown to improve adherence to evidence-based guidelines and to help optimize patient care outcomes for acute coronary syndromes. In ambulatory care, there are numerous examples of how pharmacists can help optimize medication regimens for cardiovascular disease and cardiovascular risk factor control. Community pharmacists have been successful in helping treat hyperlipidemia in patients with cardiovascular disease. While these studies have demonstrated that pharmacy-based interventions improve surrogate outcomes, there are limited well designed, randomized, controlled trials that have demonstrated that pharmacist-managed interventions improve clinical or humanistic outcomes in patients with cardiovascular disease or that such programs are cost effective.

Opportunities for pharmacists exist at each stage of cardiovascular disease management. A needs assessment should be performed to determine the level of risk factor control and appropriate medication utilization within an organization, institution, or practice site. Physician support and collaboration among multidisciplinary teams are essential to the success of the service. Potential funding sources for establishing a service should be researched, and justification for the investment must be made. Limited time and compensation are likely to be the greatest obstacles to pharmacists instituting cardiovascular services. Other key elements include employing well trained, experienced staff, utilizing a medication protocol and patient tracking database, and implementing safety measures. An opportunity exists to conduct rigorous, well designed studies to evaluate the outcomes of pharmacist-led interventions for patients with cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. American Heart Association. Heart disease and stroke statistics: 2008 [online]. Available from URL: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.187998 [Accessed 2008 Feb 20]

  2. World Health Organization. Major causes of death: a primer [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs310/en/index2.html [Accessed 2007 Oct 29]

  3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction). Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007 Aug 14; 116(7): e148–304

    Article  PubMed  Google Scholar 

  4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004 Aug 31; 110(9): e82–292

    PubMed  Google Scholar 

  5. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (writing committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). Circulation 2006 Feb 7; 113(5): 732–61

    Article  PubMed  Google Scholar 

  6. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 May 16; 113(19): 2363–72

    Article  PubMed  Google Scholar 

  7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 Jan 11; 295(2): 180–9

    Article  PubMed  CAS  Google Scholar 

  8. Qureshi AI, Suri MF, Guterman LR, et al. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001 Jul 9; 161(13): 1621–8

    Article  PubMed  CAS  Google Scholar 

  9. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 2002 Mar 15; 89(6): 653–61

    Article  PubMed  Google Scholar 

  10. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003 Jan 1; 41(1): 56–61

    Article  PubMed  Google Scholar 

  11. Stringer KA, Lopez L, Talbert RL. A call for pharmacists to improve the care of patients with myocardial infarction. Pharmacotherapy 2001 Nov; 21(11): 1317–9

    Article  PubMed  CAS  Google Scholar 

  12. Pharmaceutical Services Negotiating Committee, National Pharmaceutical Association, Royal Pharmaceutical Society of Great Britian, Pharmacy Health Link. Public health: a practical guide for community pharmacists. London: Ushers Print and Design, 2006

  13. Tsuyuki RT, Semchuk W, Poirier L. 2006 Canadian hypertension education program for the management of hypertension by pharmacists. Can Pharm J 2006; 139 Suppl. 1: 11–3

    Google Scholar 

  14. Chapman NR, Fotis MA, Yarnold PR, et al. Pharmacist interventions to improve the management of coronary artery disease. Am J Health Syst Pharm 2004 Dec 15; 61(24): 2672–8

    PubMed  Google Scholar 

  15. Bailey TC, Noirot LA, Blickensderfer A, et al. An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 2007 Mar 26; 167(6): 586–90

    Article  PubMed  Google Scholar 

  16. Scott IA, Denaro CP, Bennett CJ, et al. Achieving better in-hospital and after-hospital care of patients with acute cardiac disease. Med J Aust 2004 May 17; 180(10 Suppl.): S83–8

    PubMed  Google Scholar 

  17. O’Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005 Sep; 39(9): 1423–7

    Article  PubMed  Google Scholar 

  18. Coons JC, Fera T. Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. Am J Health Syst Pharm 2007 Jun; 64(12): 1274–8

    Article  PubMed  Google Scholar 

  19. Axtell SS, Ludwig E, Lope-Candales P. Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction. Clin Cardiol 2001 Feb; 24(2): 114–8

    Article  PubMed  CAS  Google Scholar 

  20. Donovan JL, Schroeder WS, Tran MT, et al. Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists. J Manag Care Pharm 2007 Sep; 13(7): 598–606

    PubMed  Google Scholar 

  21. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000 Nov; 20(11): 1375–83

    Article  PubMed  CAS  Google Scholar 

  22. Faulkner MA, Wadibia EC, Lucas BD, et al. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000 Apr; 20(4): 410–6

    Article  PubMed  CAS  Google Scholar 

  23. Merenich JA, Lousberg TR, Brennan SH, et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 2000 Feb 10; 85(3A): 36A–42A

    Article  PubMed  CAS  Google Scholar 

  24. DiTusa L, Luzier AB, Brady PG, et al. A pharmacy-based approach to cholesterol management. Am J Manag Care 2001 Oct; 7(10): 973–9

    PubMed  CAS  Google Scholar 

  25. Hilleman DE, Monaghan MS, Ashby CL, et al. Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. Pharmacotherapy 2001 Nov; 21(11): 1415–21

    Article  PubMed  CAS  Google Scholar 

  26. Geber J, Parra D, Beckey NP, et al. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002 Jun; 22(6): 738–47

    Article  PubMed  Google Scholar 

  27. Olson KL, Rasmussen J, Sandhoff BG, et al. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 2005 Jan 10; 165(1): 49–54

    Article  PubMed  Google Scholar 

  28. Straka RJ, Taheri R, Cooper SL, et al. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy 2005 Mar; 25(3): 360–71

    Article  PubMed  Google Scholar 

  29. Reilly V, Cavanagh M. The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist. Pharm World Sci 2003 Dec; 25(6): 294–8

    Article  PubMed  Google Scholar 

  30. Kammer RT. Pharmacist’s role in a cardiac rehabilitation program. Am J Health Syst Pharm 2004 Aug 1; 61(15): 1593–5

    PubMed  Google Scholar 

  31. Merenich JA, Olson KL, Delate T, et al. Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease. Pharmacotherapy 2007 Oct; 27(10): 1370–8

    Article  PubMed  Google Scholar 

  32. McConnell KJ, Zadvorny EB, Hardy AM, et al. Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program. Pharmacotherapy 2006 Sep; 26(9): 1333–41

    Article  PubMed  Google Scholar 

  33. McConnell KJ, Zadvorny EB, Denham AM, et al. Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus. Am J Manag Care 2007 Oct; 13(10): 560–6

    PubMed  Google Scholar 

  34. Retiring TF, Stolcpart RS, Sandhoff BG, et al. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 2006 Jun; 43(6): 1205–10

    Article  Google Scholar 

  35. Sandhoff BG, Nies LK, Olson KL, et al. Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. Am J Health Syst Pharm 2007 Jan 1; 64(1): 77–84

    Article  PubMed  Google Scholar 

  36. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002 May 27; 162(10): 1149–55

    Article  PubMed  Google Scholar 

  37. Tsuyuki RT, Olson KL, Dubyk AM. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004 Jan 15; 116(2): 130–3

    Article  PubMed  Google Scholar 

  38. Peterson GM, Fitzmaurice KD, Naunton M, et al. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther 2004 Feb; 29(1): 23–30

    Article  PubMed  CAS  Google Scholar 

  39. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007 Apr; 24 (2): 189-200

  40. Fagan SC, Touchette D, Smith JA, et al. The state of science and research in clinical pharmacy. Pharmacotherapy 2006 Jul; 26(7): 1027–40

    Article  PubMed  Google Scholar 

  41. Harris IM, Baker E, Berry TM, et al. Developing a business-practice model for pharmacy services in ambulatory settings. Pharmacotherapy 2008 Feb; 28(2): 7e–34e

    Article  Google Scholar 

  42. National Committee for Quality Assurance. Quality compass 2007. Washington, DC: National Committee for Quality Assurance, 2007

    Google Scholar 

  43. Joint Commission on Accreditation of Healthcare Organizations. Joint commission requirements [online]. Available from URL: http://www.jointcommission.org/Standards/Requirements. [Accessed 2007 Oct 29]

  44. World Medical Organization. Statement on the working relationship between physicians and pharmacists in medicinal therapy [online]. Available from URL: http://www.wma.net/e/policy/m33htn. [Accessed 2007 Oct 23]

  45. Keely JL. Pharmacist scope of practice. Ann Intern Med 2002 Jan 1; 136(1): 79–85

    PubMed  Google Scholar 

  46. Hammond RW, Schwartz AH, Campbell MJ, et al. Collaborative drug therapy management by pharmacists: 2003. Pharmacotherapy 2003 Sep; 23(9): 1210–25

    Article  PubMed  Google Scholar 

  47. Kuo GM, Buckley TE, Fitzsimmons DS, et al. Collaborative drug therapy management services and reimbursement in a family medicine clinic. Am J Health Syst Pharm 2004 Feb 15; 61(4): 343–54

    PubMed  Google Scholar 

  48. Emmerton L, Marriott J, Bessell T, et al. Pharmacists and prescribing rights: review of international developments. J Pharm Pharmaceut Sci 2005; 8(2): 217–25

    Google Scholar 

  49. Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br J Gen Pract 2003 Aug; 53(493): 600–6

    PubMed  Google Scholar 

  50. Doucette WR, Nevins J, McDonough RP. Factors affecting collaborative care between pharmacists and physicians. Res Social Adm Pharm 2005 Dec; 1(4): 565–78

    Article  PubMed  Google Scholar 

  51. Zillich AJ, McDonough RP, Carter BL, et al. Influential characteristics of physician/pharmacist collaborative relationships. Ann Pharmacother 2004 May; 38(5): 764–70

    Article  PubMed  Google Scholar 

  52. Howard M, Trim K, Woodward C, et al. Collaboration between community pharmacists and family physicians: lessons learned from the Seniors Medication Assessment Research Trial. J Am Pharm Assoc 2003 Sep; 43(5): 566–72

    Article  Google Scholar 

  53. Epplen K, Dusing-Wiest M, Freedlund J, et al. Stepwise approach to implementing ambulatory clinical pharmacy services. Am J Health Syst Pharm 2007 May 1; 64(9): 945–51

    Article  PubMed  Google Scholar 

  54. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy 2001 Nov; 21(11): 1337–44

    Article  PubMed  CAS  Google Scholar 

  55. Hilleman DE, Faulkner MA, Monaghan MS. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia. Pharmacotherapy 2004 Aug; 24(8): 1077–83

    Article  PubMed  Google Scholar 

  56. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996–2000. Pharmacotherapy 2003 Jan; 23(1): 113–32

    Article  PubMed  Google Scholar 

  57. Vora S, Cohen T. Implementing clinical services across a large health system. Am J Health Syst Pharm 2007 Mar 1; 64(5): 460, 463

    Article  PubMed  Google Scholar 

  58. Martin-Calero MJ, Machuca M, Murillo MD, et al. Structural process and implementation programs of pharmaceutical care in different countries. Curr Pharm Des 2004; 10(31): 3969–85

    Article  PubMed  CAS  Google Scholar 

  59. Simpson SH, Johnson JA, Biggs C, et al. Practice-based research: lessons from community pharmacist participants. Pharmacotherapy 2001 Jun; 21(6): 731–9

    Article  PubMed  CAS  Google Scholar 

  60. Jones EJ, Mackinnon NJ, Tsuyuki RT. Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother 2005 Sep; 39(9): 1527–33

    Article  PubMed  Google Scholar 

  61. Snella KA, Trewyn RR, Hansen LB, et al. Pharmacist compensation for cognitive services: focus on the physician office and community pharmacy. Pharmacotherapy 2004 Mar; 24(3): 372–88

    Article  PubMed  Google Scholar 

  62. Christensen DB, Farris KB. Pharmaceutical care in community pharmacies: practice and research in the US. Ann Pharmacother 2006 Jul; 40(7–8): 1400–6

    Article  PubMed  Google Scholar 

  63. Farris KB, Kumbera P, Halterman T, et al. Outcomes-based pharmacist reimbursement: reimbursing pharmacists for cognitive services. Part 1. J Manag Care Pharm 2002 Sep; 8(5): 383–93

    PubMed  Google Scholar 

  64. Suh DC. Consumer’s willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc (Wash.) 2000 Nov; 40(6): 818–27

    CAS  Google Scholar 

  65. Barner JC, Branvold A. Patients’ willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations. Res Social Adm Pharm 2005 Mar; 1(1): 77–100

    Article  PubMed  Google Scholar 

  66. Helling DK, Nelson KM, Ramirez JE, et al. Kaiser Permanente Colorado Region Pharmacy Department: innovative leader in pharmacy practice. J Am Pharm Assoc (2003) 2006 Jan; 46(1): 67–76

    Article  Google Scholar 

  67. National Community Pharmacist Association [online]. Available from URL: http://www.ncpanet.org/nipco/programs/ [Accessed 2007 Nov 7]

  68. National Lipid Association [online]. Available from URL: http://www.pharmacist.com/Content/NavigationMenu3/ContinuingEducation/Cert ificateTrainingProgram/PharmacyBasedLipidManagement/Pharma_Lipid_Mg mt.htm [Accessed 2007 Nov 7]

  69. American Pharmacists Association. Pharmacist-based lipid management [online]. Available from URL: http://www.ashpfoundation.org/MainMenuCategories/Education/Traineeships/CardiovascularTraineeship.aspx [Accessed 2007 Nov V]

  70. ASHP Foundation. Cardiovascular risk/dyslipidemia traineeship [online]. Available from URL: http://www.ashpfoundation.org/MainMenuCategories/Educa tion/Traineeships/CardiovascularTraineeship.aspx [Accessed 2007 Nov 7]

  71. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97

  72. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  73. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 Sep; 14 Suppl. 2: E1–40

    Article  PubMed  Google Scholar 

  74. Mancia G, De BG, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87

    Article  PubMed  CAS  Google Scholar 

  75. Khan NA, Hemmelgarn B, Padwal R, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2. Therapy. Can J Cardiol 2007 May 15; 23(7): 539–50

    Article  PubMed  CAS  Google Scholar 

  76. Holsclaw SL, Olson KL, Hornak R, et al. Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service. J Manag Care Pharm 2005 Jun; 11(5): 403–9

    PubMed  Google Scholar 

  77. Collins C, Kramer A, O’Day ME. Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center. Am J Health Syst Pharm 2006 Sep 15; 63(18): 1723–7

    Article  PubMed  Google Scholar 

  78. Nola KM, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc (Wash.) 2000 Mar; 40(2): 166–73

    CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente Colorado, 16601 E. Centretech Parkway, Aurora, Colorado, 80011, USA

    Karen J. McConnell PharmD, BCPS (clinical pharmacy specialist), Anne M. Denham & Kari L. Olson

  2. University of Colorado Denver School of Pharmacy, Denver, Colorado, USA

    Karen J. McConnell PharmD, BCPS (clinical pharmacy specialist), Anne M. Denham & Kari L. Olson

Authors
  1. Karen J. McConnell PharmD, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne M. Denham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kari L. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen J. McConnell PharmD, BCPS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McConnell, K.J., Denham, A.M. & Olson, K.L. Pharmacist-Led Interventions for the Management of Cardiovascular Disease. Dis-Manage-Health-Outcomes 16, 131–144 (2008). https://doi.org/10.2165/00115677-200816030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200816030-00001

Keywords

Search

Navigation